Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Wainwright, Mark; Maisch, Tim; Nonell, Santi; Plaetzer, Kristjan; Almeida, Adelaide; Tegos, George P; Hamblin, Michael R (2016)
Publisher: Elsevier
Languages: English
Types: Article
Subjects: RM, Article
Although conventional antimicrobial drugs have been viewed as miraculous cure-alls for the past 80 years, increasing antimicrobial drug resistance requires a major and rapid intervention. However, the development of novel but still conventional systemic antimicrobial agents, having only a single mode or site of action, will not alleviate the situation because it is probably only a matter of time until any such agents will also become ineffective. To continue to produce new agents based on this notion is unacceptable, and there is an increasing need for alternative approaches to the problem. By contrast, light-activated molecules called photoantimicrobials act locally via the in-situ production of highly reactive oxygen species, which simultaneously attack various biomolecular sites in the pathogenic target and therefore offer both multiple and variable sites of action. This non-specificity at the target circumvents conventional mechanisms of resistance and inhibits the development of resistance to the agents themselves. Photoantimicrobial therapy is safe and easy to implement and, unlike conventional agents, the activity spectrum of photoantimicrobials covers bacteria, fungi, viruses, and protozoa. However, clinical trials of these new, truly broad-spectrum, and minimally toxic agents have been few, and the funding for research and development is almost non-existent. Photoantimicrobials constitute one of the few ways forward through the morass of drug-resistant infectious disease and should be fully explored. In this Personal View, we raise awareness of the novel photoantimicrobial technologies that offer a viable alternative to conventional drugs in many relevant application fields, and could thus slow the pace of resistance development.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1 ECDC. Surveillance report. Annual epidemiological report. Antimicrobial resistance and healthcare-associated infections. 2014. http://ecdc.europa.eu/en/publications/Publications/antimicrobialresistance-annual-epidemiological-report.pdf (accessed Oct 15, 2015).
    • Reporting on 2010 surveillance data and 2011 epidemic intelligence data. 2012. http://ecdc.europa.eu/en/publications/Publications/ Annual-Epidemiological-Report-2012.pdf (accessed Oct 15, 2015).
    • WHO. Antimicrobial resistance. Global report on surveillance. 2014.
    • http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_ eng.pdf?ua=1 (accessed Oct 15, 2015).
    • Progress report on the action plan against the rising threats from antimicrobial resistance. 2015. http://ec.europa.eu/health/ antimicrobial_resistance/docs/2015_amr_progress_report_en.pdf (accessed Oct 16, 2015).
    • Berendonk T, Manaia CM, Merlin C, et al. Tackling antibiotic resistance: the environmental framework. Nat Rev Microbiol 2015; 13: 310-17.
    • Hwang T, Gibbs KA, Podolsky SH, Linder JA. Antimicrobial stewardship and public knowledge of antibiotics. Lancet Infect Dis 2015; 15: 1000-01.
    • Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. N Engl J Med 2013; 368: 299-302.
    • Ling LL, Schneider T, Peoples AJ, et al. A new antibiotic kills pathogens without detectable resistance. Nature 2015; 517: 455-59.
    • Hamblin M, Hassan T. Photodynamic therapy: a new antimicrobial approach to infectious disease? Photochem Photobiol Sci 2004; 3: 436-50.
    • Yin R, Hamblin MR. Antimicrobial photosensitizers: drug discovery under the spotlight. Curr Med Chem 2015; 22: 2159-85.
    • Z Biol 1900; 39: 524 (in German).
    • 12 Jesionek A, von Tappeiner H. Zur behandlung der hautcarcinome mit ulforescierenden stoefn. Arch Klin Med 1905; 82: 223 (in German).
    • Agostinis P, Berg K, Cengel KA, et al. Photodynamic therapy of cancer: an update for clinicians. CA Cancer J Clin 2011; 61: 250-81.
    • 2 3 4 5 6 7 8 9 10 11 13 14 15 16 17 18 19 21 23 26 27 31 32 33 34 22 Cieplik F, Späth A, Regensburger J, et al. Photodynamic biofilm inactivation by SAPYR-an exclusive singlet oxygen photosensitizer. Free Radic Biol Med 2013; 65: 477-87.
    • Dai T, Fuchs BB, Coleman JJ, et al. Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform. Front Microbiol 2012; 3: 120.
    • 24 Banerjee I, Douaisi MP, Mondal D, Kane RS. Light-activated nanotube-porphyrin conjugates as efective antiviral agents. Nanotechnology 2012; 23: 105101.
    • 25 Akilov O, Kosaka S, O'Riordan K, et al. The role of photosensitizer molecular charge and structure on the eficacy of photodynamic therapy against Leishmania parasites. Chem Biol 2006; 13: 839-47.
    • Maisch T, Bosl C, Szeimies RM, Love B, Abels C. Determination of the antibacterial eficacy of a new porphyrin-based photosensitizer against MRSA ex vivo. Photochem Photobiol Sci 2007; 6: 545-51.
    • Kömerik N, Wilson M, Poole S. The eefct of photodynamic action on two virulence factors of gram-negative bacteria. Photochem Photobiol 2000; 72: 676-80.
    • 28 Tubby S, Wilson M, Nair SP. Inactivation of staphylococcal virulence factors using a light-activated antimicrobial agent. BMC Microbiol 2009; 9: 211.
    • 29 de Melo W, Avci P, de Oliveira MN, et al. Photodynamic inactivation of biofilm: taking a lightly colored approach to stubborn infection. Expert Rev Anti Infect Ther 2013; 11: 669-93.
    • 30 Cieplik F, Tabenski L, Buchalla W, Maisch T. Antimicrobial photodynamic therapy for inactivation of biofilms formed by oral key pathogens. Front Microbiol 2014; 12: 405.
    • BMC Microbiol 2010; 10: 323.
    • Dahl T, Bilski P, Reszka KJ, Chignell CF. Photocytotoxicity of curcumin. Photochem Photobiol 1994; 59: 290-94.
    • Photochem Photobiol Sci 2013; 12: 1795-802.
    • Maisch T, Eichner A, Späth A, et al. Fast and efective photodynamic inactivation of multiresistant bacteria by cationic riboflavin derivatives. PLoS One 2014; 9: e111792.
    • 35 Cochrane C, Mordon SR, Lesage JC, Koncar V. New design of textile light difusers for photodynamic therapy. Mater Sci Eng C Mater Biol Appl 2013; 33: 1170-75.
    • 36 Yoshimura M, Namura S, Akamatsu H, Horio T. Antimicrobial efects of phototherapy and photochemotherapy in vivo and in vitro. Br J Dermatol 1996; 135: 528-32.
    • 37 Sahu K, Sharma M, Bansal H, Dube A, Gupta PK. Topical photodynamic treatment with poly-L-lysine-chlorin p6 conjugate improves wound healing by reducing hyperinflammatory response in Pseudomonas aeruginosa-infected wounds of mice. Lasers Med Sci 2013; 28: 465-71.
    • 38 Avci P, Gupta A, Sadasivam M, et al. Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring. Semin Cutan Med Surg 2013; 32: 41-52.
    • 39 Sellera F, Sabino CP, Ribeiro MS, et al. In vitro photoinactivation of bovine mastitis related pathogens. Photodiagnosis Photodyn Ther 2016; 13: 276-81.
    • 40 Selleraa F, Gargano RG, Libera AM, et al. Antimicrobial photodynamic therapy for caseous lymphadenitis abscesses in sheep: report of ten cases. Photodiagnosis Photodyn Ther 2015; 13: 120-02.
    • 41 Tortik N, Spaeth A, Plaetzer K. Photodynamic decontamination of foodstuf from Staphylococcus aureus based on novel formulations of curcumin. Photochem Photobiol Sci 2014; 13: 1402-09.
    • 42 Meissner P, Mandi G, Coulibaly B, et al. Methylene blue for malaria in Africa: results from a dose-finding study in combination with chloroquine. Malar J 2006; 5: 84.
    • 43 Kairyte K, Lapinskas S, Gudelis V, Luksiene Z. Efective inactivation of food pathogens Listeria monocytogenes and Salmonella enterica by combined treatment of hypericin-based photosensitization and high power pulsed light. J Appl Microbiol 2013; 112: 1144-51.
    • 44 WHO. Sixty-third World Health Assembly. Resolutions and decisions annexes. 2010. http://apps.who.int/gb/ebwha/pdf_files/ WHA63-REC1/WHA63_REC1-en.pdf (accessed Sept 10, 2016).
    • 45 de Menezes H, Rodrigues GB, Teixeira Sde P, et al. In vitro photodynamic inactivation of plant-pathogenic fungi Colletotrichum acutatum and Colletotrichum gloeosporioides with novel phenothiazinium photosensitizers. Appl Environ Microbiol 2014; 80: 1623-32.
    • 46 Arrojado C, Pereira C, Tome JP, et al. Applicability of photodynamic antimicrobial chemotherapy as an alternative to inactivate fish pathogenic bacteria in aquaculture systems. Photochem Photobiol Sci 2011; 10: 1691-700.
    • 47 Almeida J, Tome JP, Neves MG, et al. Photodynamic inactivation of multidrug-resistant bacteria in hospital wastewaters: influence of residual antibiotics. Photochem Photobiol Sci 2014; 13: 626-33.
    • 48 McCoy CP, O'Neil EJ, Cowley JF, et al. Photodynamic antimicrobial polymers for infection control. PLoS One 2014; 9: e108500.
    • 49 Felgenträger A, Maisch T, Späth A, Schröder JA, Bäumler W. Singlet oxygen generation in porphyrin-doped polymeric surface coating enables antimicrobial efects on Staphylococcus aureus. Phys Chem Chem Phys 2014; 16: 20598-607.
    • 50 Tegos G. Biodefense: trends and challenges in combating biological warfare agents. Virulence 2013; 4: 740-44.
    • 51 Demidova T, Hamblin MR. Photodynamic inactivation of Bacillus spores, mediated by phenothiazinium dyes. Appl Environ Microbiol 2005; 71: 6918-25.
    • 52 Cassidy C, Tunney MM, Magee ND, et al. Drug and light delivery strategies for photodynamic antimicrobial chemotherapy (PACT) of pulmonary pathogens: a pilot study. Photodiagnosis Photodyn Ther 2011; 8: 1-6.
    • 53 Peiris J, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nat Med 2004; 10: S88-97.
    • 54 Abbott A. Medics braced for fresh superbug. Nature 2005; 436: 758.
    • 55 Dijkshoorn L, Neme A, Seifert, H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007; 5: 939-51.
    • 56 LoBue P, Sizemore C, Castro KG. Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. MMWR Recomm Rep 2009; 58: 1-43.
    • 57 Bufie C, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol 2013; 13: 790-801.
    • 58 May M. Drug development: time for teamwork. Nature 2014; 509: S4-5.
    • 59 Sung N, Back S, Jung J, et al. Inactivation of multidrug resistant (MDR)-and extensively drug resistant (XDR)-Mycobacterium tuberculosis by photodynamic therapy. Photodiag Photodyn Ther 2013; 10: 694-702.
    • 60 Lopes R, de Godoy CH, Deana AM, et al Photodynamic therapy as a novel treatment for halitosis in adolescents: study protocol for a randomized controlled trial. Trials 2014; 14: 443.
    • 61 Figueiredo SLW, Souza SV, Botelho AC. Randomized controlled trial comparing photodynamic therapy based on methylene blue dye and fluconazole for toenail onychomycosis. Dermatol Ther 2014; 27: 43-47.
    • 62 Tardivo J, Adami F, Correa JA, Pinhal MA, Baptista MS. A clinical trial testing the eficacy of PDT in preventing amputation in diabetic patients. Photodiagnosis Photodyn Ther 2014; 11: 342-50.
    • 63 Neugebauer J, Jozsa M, Kubler A. Antimicrobial photodynamic therapy for prevention of alveolar ostitis and post-extraction pain. Mund Kiefer Gesichtschir 2004; 8: 350-55.
    • 64 Brown S. Clinical antimicrobial photodynamic therapy: phase II studies in chronic wounds. J Natl Compr Canc Netw, 2012; 10 (suppl 2): S80-83.
    • 65 Morley S, Grifiths J, Philips G, et al. Phase IIa randomized, placebo-controlled study of antimicrobial photodynamic therapy in bacterially colonized, chronic leg ulcers and diabetic foot ulcers: a new approach to antimicrobialtherapy. Br J Dermatol 2013; 168: 617-24.
    • 66 Barolet D, Boucher A. Radiant near infrared light emitting Diode exposure as skin preparation to enhance photodynamic therapy inflammatory type acne treatment outcome. Lasers Surg Med 2010; 42: 171-78.
    • 67 Sakamoto FH, Torezan L, Anderson RR. Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice: part II. Understanding parameters for acne treatment with photodynamic therapy. J Am Acad Dermatol 2010; 63: 195-211.
    • 68 Said D, Elalfy MS, Gatzioufas Z, et al. Collagen cross-linking with photoactivated riboflavin (PACK-CXL) for the treatment of advanced infectious keratitis with corneal melting. Ophthalmology 2014; 121: 1377-82.
    • 69 Garcez AS, Nunez SC, Hamblin MR, Ribeiro MS. Antimicrobial efects of photodynamic therapy on patients with necrotic pulps and periapical lesion. J Endod 2008; 34: 138-42.
    • 70 Parker S. The use of difuse laser photonic energy and indocyanine green photosensitiser as an adjunct to periodontal therapy. Br Dent J 2013; 215: 167-71.
    • 71 Arciola CR, Montanaro L, Costerton JW. New trends in diagnosis and control strategies for implant infections. Int J Artif Organs 2011; 34: 727-36.
    • 72 Chibebe Junior J, Fuchs BB, Sabino CP, et al. Photodynamic and antibiotic therapy impair the pathogenesis of Enterococcus faecium in a whole animal insect model. PLoS One 2013; 8: e55926.
    • 73 Tanaka M, Mroz P, Dai T, et al. Linezolid and vancomycin decrease the therapeutic efect of methylene blue-photodynamic therapy in a mouse model of MRSA bacterial arthritis. Photochem Photobiol 2013; 89: 679-88.
    • 74 Wellcome Trust and UK Department of Health. Review on antimicrobial resistance. Tackling drug-resistant infections globally. 2014. http://amr-review.org/ (accessed Oct 16, 2015).
    • 75 US CDC. National strategy for the combating antibiotic-resistant bacteria. 2014 http://www.cdc.gov/drugresistance/pdf/carb_ national_strategy.pdf (accessed Oct 16, 2015).
  • No related research data.
  • Discovered through pilot similarity algorithms. Send us your feedback.

Share - Bookmark

Funded by projects

  • WT

Cite this article